Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 29, 2026, 11:03 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1489–1512 of 6,078 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Matched control Clear all
Completed Phase 1 Interventional

Multiple Ascending Dose Study of Intravenously Administered BMS-986168 (BIIB092) in Patients With Progressive Supranuclear Palsy

NCT02460094
View directory record Official record
Conditions
Progressive Supranuclear Palsy
Interventions
BIIB092, Placebo
Drug
Lead sponsor
Biogen
Industry
Eligibility
41 Years to 86 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
13
States / cities
Birmingham, Alabama • Los Angeles, California • San Diego, California + 10 more
Source: ClinicalTrials.gov public record
Updated Sep 4, 2018 · Synced Oct 29, 2026, 11:03 AM EDT
Completed Phase 2 Interventional Results available

A Study to Examine the Safety, Tolerability and Effects on Abnormal Bone Formation of REGN2477 in Patients With Fibrodysplasia Ossificans Progressiva

NCT03188666
View directory record Official record
Conditions
Fibrodysplasia Ossificans Progressiva
Interventions
REGN2477, Matching placebo
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years to 60 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
3
States / cities
Rochester, Minnesota • Philadelphia, Pennsylvania • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Dec 2, 2022 · Synced Oct 29, 2026, 11:03 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Strategies for Responding to Stress

NCT03289156
View directory record Official record
Conditions
Stress
Interventions
Arousal Reappraisal, Exercise
Behavioral
Lead sponsor
University of Texas at Austin
Other
Eligibility
18 Years to 35 Years
Enrollment
160 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Nov 5, 2020 · Synced Oct 29, 2026, 11:03 AM EDT
Completed Phase 3 Interventional Results available

A Study of Cytisinicline for Smoking Cessation in Adult Smokers

NCT04576949
View directory record Official record
Conditions
Smoking Cessation
Interventions
Cytisinicline, Placebo, Behavioral support
Drug · Behavioral
Lead sponsor
Achieve Life Sciences
Industry
Eligibility
18 Years and older
Enrollment
810 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
17
States / cities
Mobile, Alabama • Phoenix, Arizona • Coral Gables, Florida + 14 more
Source: ClinicalTrials.gov public record
Updated Jan 15, 2026 · Synced Oct 29, 2026, 11:03 AM EDT
Completed Phase 3 Interventional Results available

Oral Cladribine in Early Multiple Sclerosis (MS)

NCT00725985
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Cladribine, Placebo, Rebif® new formulation (RNF)
Drug
Lead sponsor
EMD Serono Research & Development Institute, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
617 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
24
States / cities
Phoenix, Arizona • Newport Beach, California • Denver, Colorado + 21 more
Source: ClinicalTrials.gov public record
Updated Mar 22, 2021 · Synced Oct 29, 2026, 11:03 AM EDT
Recruiting Phase 3 Interventional

A Study of Seltorexant as Monotherapy in Adults and Elderly Participants With Major Depressive Disorder

NCT07573176
View directory record Official record
Conditions
Depressive Disorder, Major
Interventions
Seltorexant, Placebo
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 74 Years
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
34
States / cities
Bryant, Arkansas • Bellflower, California • Glendale, California + 27 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 29, 2026, 11:03 AM EDT
Completed No phase listed Observational Results available

Cardiovascular Outcomes in Bariatric Surgery Patients With Type 2 Diabetes

NCT03955952
View directory record Official record
Conditions
Obesity, Type2 Diabetes, Bariatric Surgery Candidate
Interventions
Bariatric Surgery
Procedure
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years to 80 Years
Enrollment
91,700 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 3, 2026 · Synced Oct 29, 2026, 11:03 AM EDT
Completed Phase 1Phase 2 Interventional

A Dose-Escalation Study Designed to Evaluate the Tolerability, Safety, Pharmacokinetics (PK), and Efficacy of Chronic Topical Ocular Application of INO-8875 in Adults With Ocular Hypertension or Primary Open-Angle Glaucoma

NCT01123785
View directory record Official record
Conditions
Glaucoma, Ocular Hypertension
Interventions
INO-8875, Placebo
Drug
Lead sponsor
Inotek Pharmaceuticals Corporation
Industry
Eligibility
18 Years to 77 Years
Enrollment
144 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Oct 15, 2012 · Synced Oct 29, 2026, 11:03 AM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

A Study To Establish The Effects Of PF-04457845 On Sleep In Healthy Volunteers

NCT01002625
View directory record Official record
Conditions
Sleep, Healthy Volunteers
Interventions
PF-04457845 / matched placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 8, 2010 · Synced Oct 29, 2026, 11:03 AM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

A Trial of Inflammatory Markers, Depressive Symptoms, and Heart Disease

NCT00208117
View directory record Official record
Conditions
Depression, Coronary Artery Disease (CAD), Acute Coronary Syndrome (ACS)
Interventions
Sertraline (Zoloft), Simvastatin (Zocor)
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
18 Years to 60 Years
Enrollment
7 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2009
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 31, 2012 · Synced Oct 29, 2026, 11:03 AM EDT
Completed Phase 3 Interventional Results available

ENVISION: A Study to Evaluate the Efficacy and Safety of Givosiran (ALN-AS1) in Patients With Acute Hepatic Porphyrias (AHP)

NCT03338816
View directory record Official record
Conditions
Acute Hepatic Porphyria, Acute Intermittent Porphyria, Porphyria, Acute Intermittent, Acute Porphyria, Hereditary Coproporphyria (HCP), Variegate Porphyria (VP), ALA Dehydratase Deficient Porphyria (ADP)
Interventions
Givosiran, Placebo
Drug
Lead sponsor
Alnylam Pharmaceuticals
Industry
Eligibility
12 Years and older
Enrollment
94 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
10
States / cities
Little Rock, Arkansas • San Francisco, California • Boston, Massachusetts + 7 more
Source: ClinicalTrials.gov public record
Updated Apr 22, 2024 · Synced Oct 29, 2026, 11:03 AM EDT
Terminated Phase 2 Interventional

A Randomized, Placebo-controlled, Double-blind Phase 2 Study With OSI-906 in Patients With Advanced HCC

NCT01101906
View directory record Official record
Conditions
Advanced Hepatocellular Carcinoma (HCC)
Interventions
OSI-906, Placebo
Drug
Lead sponsor
Astellas Pharma Inc
Industry
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
6
States / cities
Los Angeles, California • New Orleans, Louisiana • Portland, Oregon + 2 more
Source: ClinicalTrials.gov public record
Updated Nov 20, 2024 · Synced Oct 29, 2026, 11:03 AM EDT
Completed Phase 1 Interventional Results available

MK-1942/Donepezil Interactions in Participants With Alzheimer's Disease (MK-1942-005)

NCT04308304
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
MK-1942, Donepezil, Placebo
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
50 Years to 85 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
4
States / cities
Rogers, Arkansas • Hallandale, Florida • Decatur, Georgia + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 15, 2024 · Synced Oct 29, 2026, 11:03 AM EDT
Completed Phase 2 Interventional

A Clinical Study of Efinopegdutide in Participants With Precirrhotic Nonalcoholic Steatohepatitis (NASH) (MK-6024-013)

NCT05877547
View directory record Official record
Conditions
Non-alcoholic Fatty Liver Disease, Fatty Liver, Nonalcoholic, NAFLD, Nonalcoholic Fatty Liver Disease, Nonalcoholic Steatohepatitis
Interventions
Efinopegdutide, Semaglutide, Placebo
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years to 80 Years
Enrollment
381 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
42
States / cities
Chandler, Arizona • Peoria, Arizona • Tucson, Arizona + 36 more
Source: ClinicalTrials.gov public record
Updated Jan 12, 2026 · Synced Oct 29, 2026, 11:03 AM EDT
Completed Phase 1 Interventional

A Study to Evaluate Safety, Tolerability and Pharmacokinetics of MNKD-201 in Patients With Idiopathic Pulmonary Fibrosis

NCT07344558
View directory record Official record
Conditions
Idiopathic Pulmonary Fibrosis (IPF)
Interventions
MNKD-201(Nintedanib DPI), Placebo
Drug
Lead sponsor
Mannkind Corporation
Industry
Eligibility
40 Years to 85 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
9
States / cities
Fresno, California • Palm Springs, California • Doral, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Jul 22, 2026 · Synced Oct 29, 2026, 11:03 AM EDT
Completed Phase 2 Interventional

Placebo-Controlled Study to Evaluate the Safety and Efficacy of OPN-305 in Preventing Delayed Renal Graft Function

NCT01794663
View directory record Official record
Conditions
Delayed Graft Function
Interventions
OPN-305, Placebo
Drug
Lead sponsor
Opsona Therapeutics Ltd.
Industry
Eligibility
18 Years and older
Enrollment
252 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
14
States / cities
Los Angeles, California • Washington D.C., District of Columbia • Tampa, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Feb 16, 2017 · Synced Oct 29, 2026, 11:03 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Clinical and Neurobiological Effects of Cannabis Dependence in Young Adults

NCT00656487
View directory record Official record
Conditions
Cannabis Dependence, Cannabis Withdrawal
Interventions
rimonabant, placebo
Drug
Lead sponsor
The Scripps Research Institute
Other
Eligibility
21 Years to 30 Years
Enrollment
66 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2011
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Jun 19, 2017 · Synced Oct 29, 2026, 11:03 AM EDT
Completed Phase 2 Interventional Results available

Efficacy, Safety, and Tolerability Study of Oral Full-Spectrum MicrobiotaTM (CP101) in Subjects With Recurrent C. Diff

NCT03110133
View directory record Official record
Conditions
Clostridium Difficile Infection Recurrence
Interventions
Full Spectrum Microbiota, Placebo
Drug
Lead sponsor
Finch Research and Development LLC.
Industry
Eligibility
18 Years and older
Enrollment
206 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
54
States / cities
Scottsdale, Arizona • Los Angeles, California • Murrieta, California + 48 more
Source: ClinicalTrials.gov public record
Updated Oct 5, 2022 · Synced Oct 29, 2026, 11:03 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Contrast Ultrasound Perfusion Imaging in Peripheral Arterial Disease (PAD)

NCT01377649
View directory record Official record
Conditions
Peripheral Arterial Disease
Interventions
Not listed
Lead sponsor
Oregon Health and Science University
Other
Eligibility
19 Years and older
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2016
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Sep 27, 2016 · Synced Oct 29, 2026, 11:03 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

The Effects of an Acute High-intensity Exercise on Heart and Brain Function in People With Spinal Cord Injury

NCT06274658
View directory record Official record
Conditions
Autonomic Nervous System Disease, Spinal Cord Injuries, Cognition
Interventions
High-intensity interval exercise
Behavioral
Lead sponsor
State University of New York at Buffalo
Other
Eligibility
18 Years to 70 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Sep 3, 2025 · Synced Oct 29, 2026, 11:03 AM EDT
Terminated Phase 4 Interventional Accepts healthy volunteers

Oral Vancomycin for Secondary Prophylaxis of Clostridium Difficile Infection (CDI)

NCT04000555
View directory record Official record
Conditions
Clostridium Difficile Infection, Clostridium Difficile Infection Recurrence
Interventions
Oral Vancomycin, Placebo
Drug · Other
Lead sponsor
University of South Florida
Other
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2022
U.S. locations
2
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Apr 21, 2023 · Synced Oct 29, 2026, 11:03 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Assessment of Deep Gray Matter Anatomic Changes in RRMS Patients Treated With Gilenya® With and Without Cognitive Impairment Over a 2 Year Period Using NeuroQuant, NeuroQuarc and ANAM

NCT05684016
View directory record Official record
Conditions
Multiple Sclerosis, Relapsing-Remitting
Interventions
NeuroQuant, Automated Neuropsychological Assessment Matrices, EDSS, Physical Examination
Other
Lead sponsor
George Washington University
Other
Eligibility
18 Years to 55 Years
Enrollment
75 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2016
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Jan 13, 2023 · Synced Oct 29, 2026, 11:03 AM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate the Effects of LCI699 on Cortisol in Participants With Hypertension

NCT00817414
View directory record Official record
Conditions
Hypertension
Interventions
LCI699-matching placebo, LCI699
Drug
Lead sponsor
Novartis
Industry
Eligibility
18 Years to 75 Years
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
10
States / cities
Beverly Hills, California • Buena Park, California • Harbor City, California + 7 more
Source: ClinicalTrials.gov public record
Updated Jun 2, 2021 · Synced Oct 29, 2026, 11:03 AM EDT
Not listed No phase listed Observational Accepts healthy volunteers

Biorepository: Indiana Health Study

NCT00741416
View directory record Official record
Conditions
Coronary Artery Disease, Heart Disease, Healthy
Interventions
Not listed
Lead sponsor
Fairbanks Institute
Other
Eligibility
18 Years and older
Enrollment
1,400 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2013
U.S. locations
14
States / cities
Avon, Indiana • Brownsburg, Indiana • Franklin, Indiana + 6 more
Source: ClinicalTrials.gov public record
Updated Jul 1, 2011 · Synced Oct 29, 2026, 11:03 AM EDT